Item 4.02.
|
Non-Reliance on
Previously Issued Financial Statements or a
Related Audit Report or Completed Interim Review.
|
(a) On February 21, 2019, Eidos Therapeutics, Inc. (the
Company, our or we) disclosed in a Current Report on Form
8-K
(the Form
8-K)
that, on February 15, 2019, we
dismissed PricewaterhouseCoopers LLP (PwC) as the Companys independent registered public accounting firm following PwCs notification to the Company that (a) information had come to PwCs attention that required it
and the Company to evaluate a potential independence rule violation resulting from PwCs provision of certain
non-audit
services to affiliates of the Company during the audit periods for the years ended
December 31, 2016 and December 31, 2017, and subsequently, and (b) PwCs audit report on the financial statements as of and for the years ended December 31, 2017 and 2016 should not be relied upon. We further disclosed that,
on February 18, 2019, the Audit Committee (the Committee) of the Companys Board of Directors engaged Ernst & Young LLP as the Companys independent registered public accounting firm to audit the Companys
financial statements for its year ended December 31, 2018 and to
re-audit
the Companys financial statements for the years ended December 31, 2017 and 2016 (the Applicable Periods).
On March 29, 2019, during the course of the Companys financial statement close process for the year ended December 31, 2018 and
re-audit
of the Applicable Periods, the Committee, after discussion with management and the Companys new independent registered public accountants, Ernst & Young LLP, determined that a restatement of
the prior period financial statements described below is required in order to properly account for the Companys Series Seed convertible preferred stock, convertible notes and Series B convertible preferred stock and the related tranche
liabilities, embedded derivatives, and beneficial conversion features, as applicable, within those instruments.
The Company intends to include in its
Annual Report on Form
10-K
for the year ended December 31, 2018 restated financial information for the first three quarterly periods in the year ended December 31, 2018 to properly account for the
Companys Series Seed convertible preferred stock, convertible notes and Series B convertible preferred stock and the related tranche liabilities, embedded derivatives, and beneficial conversion features, as applicable, within those
instruments. Accordingly, the condensed interim financial statements previously reported for these periods should no longer be relied upon. All such adjustments to the results for the affected interim periods during the year ended December 31,
2018 are
non-cash
adjustments and do not impact the amounts previously reported for the Companys cash and cash equivalents, nor do they relate to the Companys operating performance or financial
condition.
In consideration of these adjustments, the Company expects to report in its Annual Report on Form
10-K
for the year ended December 31, 2018 a material weakness in internal controls related to the accounting for complex debt and equity transactions and ineffective disclosure controls. The Company is in the process of remediating the material
weakness and improving its disclosure controls by hiring additional finance and accounting personnel and implementing systems to strengthen its internal technical accounting capabilities and disclosure controls processes and procedures.
2